Peloton Therapeutics

May 24, 2019

Time to restock big pharma’s leaking pipeline

The number of late-stage assets in the hands of the industry’s behemoths is shrinking, and this can only put more pressure on companies to do deals.

May 21, 2019

Merck sees potential in Peloton

Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively little clinical data.

April 10, 2019

Venture funding slowdown continues in first quarter of 2019

Venture funding drops again, but there’s no need to panic yet.

October 18, 2016

Peloton Therapeutics

Time to restock big pharma’s leaking pipeline

Merck sees potential in Peloton

Venture funding slowdown continues in first quarter of 2019

Biotech venture funding shrinks as post-boom shape emerges

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Shock revelation sees Biogen erase its aducanumab losses

Vertex’s double cystic fibrosis surprise

Bristol might play a role in front-line lung cancer after all

Bloated on arrival? Biotech's weightiest new issues

Uncovering biopharma’s hidden treasures